“…A notable example and a poster child of personalised oncology are PARP1/2 inhibitors (PARPi) that selectively kill HR‐deficient (HRD) cancer cells by preventing repair of DNA gaps or single‐strand breaks (SSBs) (
Slade, 2020). Inhibitors of cell cycle checkpoints such as CHK1 and WEE1 can also eliminate HRD cancers by pushing cancer cells through the cell cycle despite unrepaired DNA damage and causing death by mitotic catastrophe (Groelly et al, 2022). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online
Artículo
Texto